JP2019514401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514401A5 JP2019514401A5 JP2018557875A JP2018557875A JP2019514401A5 JP 2019514401 A5 JP2019514401 A5 JP 2019514401A5 JP 2018557875 A JP2018557875 A JP 2018557875A JP 2018557875 A JP2018557875 A JP 2018557875A JP 2019514401 A5 JP2019514401 A5 JP 2019514401A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- effector
- nucleic acid
- shmir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 45
- 150000007523 nucleic acids Chemical class 0.000 claims 45
- 102000039446 nucleic acids Human genes 0.000 claims 45
- 239000012636 effector Substances 0.000 claims 41
- 230000000295 complement effect Effects 0.000 claims 21
- 241000700721 Hepatitis B virus Species 0.000 claims 12
- 239000002679 microRNA Substances 0.000 claims 8
- 238000011144 upstream manufacturing Methods 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108020005065 3' Flanking Region Proteins 0.000 claims 2
- 108020005029 5' Flanking Region Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000980 entecavir Drugs 0.000 claims 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332245P | 2016-05-05 | 2016-05-05 | |
| US62/332,245 | 2016-05-05 | ||
| PCT/AU2017/050413 WO2017190197A1 (en) | 2016-05-05 | 2017-05-05 | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019514401A JP2019514401A (ja) | 2019-06-06 |
| JP2019514401A5 true JP2019514401A5 (cg-RX-API-DMAC7.html) | 2020-04-30 |
Family
ID=60202535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557875A Pending JP2019514401A (ja) | 2016-05-05 | 2017-05-05 | Ｂ型肝炎ウイルス（ｈｂｖ）感染を治療するための試薬およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11535851B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3452595A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019514401A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102358280B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109415733A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017260580B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3023185A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH12018502320A1 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2021113126A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201809753YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017190197A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3452595A4 (en) * | 2016-05-05 | 2020-02-19 | Benitec Biopharma Limited | REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF |
| WO2020100994A1 (ja) * | 2018-11-16 | 2020-05-22 | 公益財団法人東京都医学総合研究所 | Ｂ型肝炎ウイルスの複製阻害組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| RU2217161C2 (ru) * | 1997-08-26 | 2003-11-27 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) | Способ лечения вирусного гепатита |
| IL159756A0 (en) * | 2001-07-12 | 2004-06-20 | Univ Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| US8575327B2 (en) * | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| EP2316942B1 (en) | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| WO2008147430A2 (en) * | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| CN101603042B (zh) | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| JP2012528588A (ja) * | 2009-06-05 | 2012-11-15 | ソル，ダイ‐ウ | 単一またはマルチ標的遺伝子を抑制するマルチ−シストロンｓｈＲＮＡ発現カセット |
| US20130267429A1 (en) * | 2009-12-21 | 2013-10-10 | Lawrence Livermore National Security, Llc | Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes |
| SI3124610T1 (sl) | 2010-10-28 | 2019-08-30 | Benitec Biopharma Limited | Zdravljenje HBV |
| WO2013003520A1 (en) * | 2011-06-30 | 2013-01-03 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| HRP20220607T1 (hr) * | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| WO2014117050A2 (en) * | 2013-01-26 | 2014-07-31 | Mirimus, Inc. | Modified mirna as a scaffold for shrna |
| CN103088026A (zh) | 2013-02-01 | 2013-05-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 抗乙型肝炎病毒人工miRNA及其组合 |
| PL243776B1 (pl) * | 2013-09-02 | 2023-10-09 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Cząsteczka kwasu nukleinowego, kaseta ekspresyjna, wektor ekspresyjny, komórka eukariotycznego gospodarza i zastosowanie cząsteczki kwasu nukleinowego w terapii chorób wywoływanych ekspansją trójnukleotydowych powtórzeń typu CAG |
| HK1251010A1 (zh) * | 2015-05-06 | 2019-01-18 | Benitec IP Holdings Inc. | 用於治疗乙型肝炎病毒(hbv)感染的试剂及用途 |
| EP3452595A4 (en) * | 2016-05-05 | 2020-02-19 | Benitec Biopharma Limited | REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF |
-
2017
- 2017-05-05 EP EP17792296.0A patent/EP3452595A4/en not_active Withdrawn
- 2017-05-05 RU RU2021113126A patent/RU2021113126A/ru unknown
- 2017-05-05 CA CA3023185A patent/CA3023185A1/en active Pending
- 2017-05-05 KR KR1020187035341A patent/KR102358280B1/ko not_active Expired - Fee Related
- 2017-05-05 AU AU2017260580A patent/AU2017260580B2/en not_active Ceased
- 2017-05-05 RU RU2018142797A patent/RU2748806C2/ru active
- 2017-05-05 SG SG11201809753YA patent/SG11201809753YA/en unknown
- 2017-05-05 WO PCT/AU2017/050413 patent/WO2017190197A1/en not_active Ceased
- 2017-05-05 JP JP2018557875A patent/JP2019514401A/ja active Pending
- 2017-05-05 CN CN201780040430.8A patent/CN109415733A/zh active Pending
- 2017-05-05 US US16/098,759 patent/US11535851B2/en active Active
-
2018
- 2018-11-05 PH PH12018502320A patent/PH12018502320A1/en unknown
-
2022
- 2022-09-27 AU AU2022241489A patent/AU2022241489A1/en not_active Abandoned
- 2022-11-18 US US18/056,929 patent/US20230093951A1/en not_active Abandoned